Cowen Reiterates Outperform Rating on Teladoc (TDOC) Following Raised Revenue Guidance

Cowen analyst Charles Rhyee reiterated an Outperform rating and $161.00 price target on Teladoc (NYSE: TDOC) after the company raised its 2021 revenue guidance to $2.03B at an industry conference (vs. prior $2.015B-$2.025B, consensus of $2.02B), and reiterated its prelim 2022 guide of $2.6B.

Rhyee notes TDOC "also highlighted its value proposition as a mult-channel, fully integrated strategic partner; momentum in multi-product sales; a strong 2022 selling season; and its intentions to expand into value-based care."

For an analyst ratings summary and ratings history on Teladoc click here. For more ratings news on Teladoc click here.

Shares of Teladoc closed at $82.18 yesterday.

You May Also Be Interested In

• Seaport Global Securities Starts ADI Global Distribution (ADIG) at Buy
• Bernstein SocGen Group Reiterates Outperform Rating on Adyen NV (ADYEN:NA) (ADYYF), 'Can we now also get some AI winner premium?'
• Cellebrite (CLBT) PT Lowered to $15 at DA Davidson Following Q2 Miss